July 26, 2019
A key PIII trial targeting Opdivo’s (nivolumab) first-line use in non-small cell lung cancer (NSCLC) has yielded mixed overall survival (OS) results, with Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1 inhibitor delivering a success for its I/O-I/O pairing with Yervoy (ipilimumab), but not...read more